Robert Dickey IV - 15 Aug 2025 Form 4 Insider Report for Vyome Holdings, Inc (RSLS)

Reporting relationship: Chief Financial Officer
Issuer ticker: RSLS
Reported as of: 15 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Sep 2025, 21:21:17 UTC
Prior SEC filing: 17 Aug 2023
Source filing: View source filing
Reporting owner signature: /s/ Robert Dickey

Key filing fact

Robert Dickey IV filed Form 4 for Vyome Holdings, Inc (RSLS) on 11 Sep 2025.

Key facts

This page summarizes Robert Dickey IV's Form 4 filing for Vyome Holdings, Inc (RSLS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 11 Sep 2025, 21:21.

Change

Previous filing in this sequence was filed on 17 Aug 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001466862 Primary reporting owner

Dickey Robert IV

Relationship: Chief Financial Officer
Address: HARVARD SQUARE,, ONE MIFFLIN PLACE, SUITE 400, CAMBRIDGE
Signature: /s/ Robert Dickey
Signature date: 11 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HIND transaction

Common Stock

Award

Transaction value
Shares: +762
Change %
Price
Shares after: 762
Date: 15 Aug 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 762 shares of the Issuer's common stock in exchange for 3,810,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement.